Zacks: Brokerages Anticipate VERONA PHARMA P/S (VRNA) Will Announce Earnings of -$0.50 Per Share
Equities research analysts predict that VERONA PHARMA P/S (NASDAQ:VRNA) will report earnings of ($0.50) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for VERONA PHARMA P/S’s earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.67). VERONA PHARMA P/S reported earnings of ($0.64) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 21.9%. The business is expected to announce its next earnings results on Tuesday, February 26th.
Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover VERONA PHARMA P/S.
VERONA PHARMA P/S (NASDAQ:VRNA) last posted its quarterly earnings data on Tuesday, November 6th. The company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.26.
An institutional investor recently bought a new position in VERONA PHARMA P/S stock. Foresite Capital Management IV LLC acquired a new stake in shares of VERONA PHARMA P/S (NASDAQ:VRNA) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 8,302 shares of the company’s stock, valued at approximately $104,000. VERONA PHARMA P/S makes up about 0.0% of Foresite Capital Management IV LLC’s investment portfolio, making the stock its 21st largest position. Foresite Capital Management IV LLC owned 0.06% of VERONA PHARMA P/S as of its most recent SEC filing. Institutional investors and hedge funds own 56.23% of the company’s stock.
VERONA PHARMA P/S stock opened at $10.90 on Tuesday. The stock has a market capitalization of $153.16 million, a P/E ratio of -4.52 and a beta of -1.37. VERONA PHARMA P/S has a 1-year low of $10.19 and a 1-year high of $25.55.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Further Reading: Market Capitalization in the Stock Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.